Tempus AI, Inc.
TEM · NASDAQ
Analyst ratings
strong_buy · 9 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 16, 2026 | Guggenheim | Maintains | Buy | $65.00 |
| June 1, 2026 | Needham | Reiterates | Buy | $75.00 |
| June 1, 2026 | BTIG | Reiterates | Buy | $80.00 |
| May 11, 2026 | HC Wainwright & Co. | Maintains | Buy | $64.00 |
| May 8, 2026 | BTIG | Maintains | Buy | $80.00 |
| May 6, 2026 | TD Cowen | Maintains | Buy | $68.00 |
| March 30, 2026 | Guggenheim | Maintains | Buy | $60.00 |
| March 11, 2026 | Needham | Reiterates | Buy | $75.00 |
| March 9, 2026 | HC Wainwright & Co. | Maintains | Buy | $95.00 |
| March 3, 2026 | Morgan Stanley | Maintains | Overweight | $70.00 |
| February 25, 2026 | JP Morgan | Maintains | Neutral | $60.00 |
| February 25, 2026 | Needham | Maintains | Buy | $75.00 |
| February 25, 2026 | BTIG | Maintains | Buy | $90.00 |
| December 22, 2025 | Canaccord Genuity | Maintains | Buy | $80.00 |
| December 15, 2025 | JP Morgan | Maintains | Neutral | $80.00 |
| December 2, 2025 | Morgan Stanley | Maintains | Overweight | $85.00 |
| November 25, 2025 | BTIG | Maintains | Buy | $105.00 |
| November 11, 2025 | Piper Sandler | Maintains | Neutral | $80.00 |
| November 11, 2025 | Morgan Stanley | Maintains | Overweight | $80.00 |
| November 7, 2025 | HC Wainwright & Co. | Maintains | Buy | $89.00 |
| November 5, 2025 | Canaccord Genuity | Maintains | Buy | $95.00 |
| November 5, 2025 | Needham | Maintains | Buy | $100.00 |
| November 5, 2025 | BTIG | Reiterates | Buy | $96.00 |
| October 22, 2025 | Piper Sandler | Maintains | Neutral | $105.00 |
| October 22, 2025 | BTIG | Maintains | Buy | $96.00 |
| September 26, 2025 | Guggenheim | Maintains | Buy | $95.00 |
| September 12, 2025 | HC Wainwright & Co. | Maintains | Buy | $98.00 |
Revenue growth sustainability and path to profitability
Tempus AI's 36.1% year-over-year revenue growth to $348.12 million, combined with consistent earnings beats — most recently by $0.08 per share — signals strong operational momentum. Analysts at TD Cowen, BTIG Research, and Needham maintain buy ratings, citing diagnostics momentum and AI platform expansion as durable growth drivers.
Despite revenue growth, Tempus AI continues to post significant net losses, with forecasts projecting a net loss per share of $2.04 next year, worsening from $1.41. The stock is also down 23% over the past year, raising serious questions about whether the company can ever translate top-line growth into sustainable profitability.
Analyst consensus and long-term valuation credibility
Nine analysts hold buy ratings on Tempus AI, with firms like BTIG Research setting a $80 price target and Needham at $75. TD Cowen recently raised its target to $68, reflecting confidence in the company's AI platform expansion, FDA-related product gains, and long-term competitive positioning in the healthcare AI space.
The analyst community is deeply divided, with a consensus rating of only 'Hold' and a price target of $68.54. HC Wainwright slashed its target from $95 to $64, Freedom Capital only upgraded to 'hold,' and two analysts maintain sell ratings — reflecting significant uncertainty about whether current valuations are justified.
Short-term technical outlook and market sentiment
Technical indicators show Tempus AI in a rising short-term trend, with a buy signal triggered from a pivot bottom in mid-July 2025 and a 3-month MACD buy signal. The stock has risen in 7 of the last 10 trading days and is forecast to gain approximately 5.75% over the next 3 months.
Barchart's composite technical analysis rates Tempus AI at only 16% sell overall, but long-term indicators — including the 150-day, 200-day, and 100-200 day MA crossover — all signal sell. Signal strength is rated 'Weak' and direction 'Weakest,' suggesting the broader technical structure remains under pressure.